Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-26
2005-07-26
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S211080, C514S218000, C514S222200, C514S222500, C514S228200, C514S234500, C514S249000, C514S253040, C514S274000, C514S275000, C514S300000, C514S303000, C540S488000, C540S489000, C540S492000, C540S545000, C544S003000, C544S008000, C544S058600, C544S127000, C544S310000, C544S331000, C544S349000, C544S362000, C546S118000, C546S009000, C546S123000
Reexamination Certificate
active
06921759
ABSTRACT:
Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
REFERENCES:
patent: 3945995 (1976-03-01), Yamada et al.
patent: 4416884 (1983-11-01), Ishikawa et al.
patent: 4996213 (1991-02-01), Mendes et al.
patent: 5294620 (1994-03-01), Ratcliffe et al.
patent: 5633362 (1997-05-01), Nagarajan et al.
patent: 5753666 (1998-05-01), Beasley et al.
patent: 5766944 (1998-06-01), Ruiz
patent: 5945431 (1999-08-01), Jin et al.
patent: 6211376 (2001-04-01), Romines et al.
patent: 6262055 (2001-07-01), Young et al.
patent: 6294547 (2001-09-01), Oka et al.
patent: 6306891 (2001-10-01), Selnick et al.
patent: 6380249 (2002-04-01), Young et al.
patent: 6525042 (2003-02-01), Kobayashi et al.
patent: WO 96/25399 (1996-08-01), None
patent: WO 98/11073 (1998-03-01), None
patent: WO 98/13350 (1998-04-01), None
patent: WO 99/10347 (1999-03-01), None
patent: WO 99/15526 (1999-04-01), None
patent: WO 99/32450 (1999-07-01), None
patent: WO 00/03992 (2000-01-01), None
patent: WO 01/00578 (2001-01-01), None
patent: WO 02/04443 (2002-01-01), None
patent: WO 02/06246 (2002-01-01), None
patent: PCT/US 02/25666 (2002-08-01), None
patent: PCT/US 02/27151 (2002-08-01), None
patent: WO 03/035076 (2003-05-01), None
patent: WO 03/035077 (2003-05-01), None
Pommier et al., Retroviral Integrase Inhibitors Year 2000: Update and Perspectives, Antiviral Research, vol. 47, pp. 139-148, Sep. 2000.
De Clercq, Erik, New Anti-HIV Agents and Targets, Medicinal Research Reviews, vol. 22, No. 6, pp. 531-565, 2002.
J. Bedard et al., “Antiviral Properties of a Series of 1,6-Naphthyridine and 7,8-Dihydroisoquinoline Derivatives Exhibiting Potent Activity Against Human Cytomegalovirus”, 2000, vol. 44, Antimicrobial Agents and Chemotherapy.
CAPLUS Accession No. 2001:923611, Kiyama et al., “Dual divalent metal ion chelators as HIV integrase inhibitors”, abstract of WO 01/95905, Assignee: Shionogi & Co., Ltd. (2001).
Abstract of WO 02/070486 from http://ipdl.wipo.int (Fuji et al., “Nitrogen-Containing Heteroaryl Compounds Having HIV Integrase Inhibitory Activity”, Assignee: Shionogi & Co., Ltd.), 2002.
L. Chan et al., “Discovery of 1,6-Naphthyridines as a Novel Class of Potent and Selective Human Cytomegalovirus Inhibitors”, J. Med. Chem., vol. 42, No. 16, pp. 3023-3025 (1999).
Derwent Abstract No. 2002-732783, M. Fuji, “New Nitrogenous Heteroaromatic Compounds Are HIV Integrase Inhibitors For Treating HIV Infections, AIDS and AIDS-related Diseases”, Abstract of WO 02/070491, Assignee: Shionogi & Co., Ltd. (2002).
M. Ouali et al., “Modeling of the Inhibition of Retroviral Integrases by Styrylquinoline Derivatives”, J. Med. Chem., vol. 43, pp. 1949-1957 (2000).
CAPLUS Accession No. 2001:923611, R. Kiyama et al., “Dual Divalent Metal Ion Chelators as HIV Integrase Inhibitors”, Abstract of WO 01/95905, Assignee: Shionogi & Co., Ltd., Japan (2001).
L. Ratner et al., “Complete Nucleotide sequence of the AIDS virus, HTLV-III”, Nature, vol. 313, pp. 277-284 (Jan. 24, 1985).
H. Toh et al., “Close structural resemblance between putative polymerase of a Drosophila transposable genetic element 17.6 and pol gene product of Moloney murine leukaemia virus”, The EMBO Journal, vol. 4, No. 5, pp. 1267-1272 (1985).
M. D. Power et al., “Nucleotide Sequence of SRV-1, Type D Simian Acquired Immune Deficiency Syndrome Retrovirus”, Science, vol. 231, pp. 1567-1572 (1986).
L. H. Pearl et al., “A structural model for the retroviral proteases”, Nature, vol. 329, pp. 351-354 (Sep. 24, 1987).
Derwent Abstract No. 97-048296/05 (Abstract of JP 08301849-A, Takeda Chem. Ind. Ltd., “New heterocyclic carboxamide derivs.—useful in pharmaceuticals as tachykinin receptor inhibitors”), 1996.
Chemical Abstracts No. 33-2525 ; (Abstract of Otiai et al., “Synthesis of 2,5 naphthyridine derivatives. II”, J. Pharm. Soc. Japan, vol. 58, pp. 764-770 (1938)).
U.S. Appl. No. 10/333,431, filed Jul. 11, 2001, Gardelli et al.
U.S. Appl. No. 10/218,537, filed Aug. 14, 2002, Anthony et al.
Anthony Neville J.
Bennett Jennifer J.
Egbertson Melissa
Embrey Mark
Fisher Thorsten E.
Coleman Brenda
Merck & Co. , Inc.
LandOfFree
Aza- and polyaza-naphthalenyl carboxamides useful as HIV... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aza- and polyaza-naphthalenyl carboxamides useful as HIV..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aza- and polyaza-naphthalenyl carboxamides useful as HIV... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3410931